Aiming to capitalize on the flood of Phase III trial data on lixisenatide that has already started to flow, Zealand Pharma A/S is launching an initial public offering (IPO) on the Copenhagen Stock Exchange that could gross $126.1 million (DKK 671.3 million), excluding any overallotments.(BioWorld Today) Read More
